Cargando…

Immune combinational therapy targeting OX40 and IDO synergistically enhances efficacy of a cancer vaccine

Detalles Bibliográficos
Autores principales:	Berrong, Zuzana, Ahmad, Shamim, Abu Eid, Rasha, El Andaloussi, Abdeljabar, Sen, Tanusree, Stewart, Ross, Hammond, Scott A, Shrimali, Rajeev, Mkrtichyan, Mikayel, Khleif, Samir N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292459/ http://dx.doi.org/10.1186/2051-1426-2-S3-P226

Ejemplares similares

Functional redundancy of PI3K isoforms in conventional T cells provides a selective Treg-targeting strategy through inhibition of PI3K-delta isoform
por: Ahmad, Shamim, et al.
Publicado: (2014)

Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy
por: Shrimali, Rajeev, et al.
Publicado: (2017)

AKT inhibition mitigates terminal differentiation and preserves central memory phenotype of CD8 T cells
por: Abu Eid, Rasha, et al.
Publicado: (2014)

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy
por: Mkrtichyan, Mikayel, et al.
Publicado: (2013)

Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8(+) T-cell proliferation and survival
por: Abu Eid, Rasha, et al.
Publicado: (2015)

IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
por: Nandre, Rahul, et al.
Publicado: (2022)

Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer
por: Rahma, Osama E, et al.
Publicado: (2014)

OX40L–OX40 Signaling in Atopic Dermatitis
por: Furue, Masutaka, et al.
Publicado: (2021)

OX40/OX40 Ligand Interactions in T-Cell Regulation and Asthma
por: Kaur, Davinder, et al.
Publicado: (2012)

OX40/OX40L axis: not a friend in autoimmunity
por: Ueno, Hideki, et al.
Publicado: (2015)

Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome
por: Kawana, Yuki, et al.
Publicado: (2021)

IL-10(−/−) Enhances DCs Immunity Against Chlamydia psittaci Infection via OX40L/NLRP3 and IDO/Treg Pathways
por: Li, Qiang, et al.
Publicado: (2021)

Airway Wall Expression of OX40/OX40L and Interleukin-4 in Asthma
por: Siddiqui, Salman, et al.
Publicado: (2010)

Expression of gp34 (OX40 Ligand) and OX40 on Human T Cell Clones
por: Takasawa, Naruhiko, et al.
Publicado: (2001)

Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia
por: Cui, Dawei, et al.
Publicado: (2019)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

OX40L-OX40 Interactions: A Possible Target for Gastrointestinal Autoimmune Diseases
por: Mahmood, Tahrin, et al.
Publicado: (2012)

Crucial role of OX40/OX40L signaling in a murine model of asthma
por: Lei, Wei, et al.
Publicado: (2018)

Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis
por: Zhou, Xiaoling, et al.
Publicado: (2022)

OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis—Focus on Rocatinlimab and Amlitelimab
por: Lé, Ana Maria, et al.
Publicado: (2022)

OX40/OX40L in systemic lupus erythematosus: Association with disease activity and lupus nephritis
por: Farres, Mohamed N., et al.
Publicado: (2011)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

New Complex Chromosomal Translocation in Chronic Myeloid Leukaemia: t(9;18;22)(q34;p11;q11)
por: El Andaloussi, Abdeljabar, et al.
Publicado: (2007)

SANTAVAC(TM): Summary of Research and Development
por: Lokhov, Petr G., et al.
Publicado: (2019)

The OX40/OX40L Axis Regulates T Follicular Helper Cell Differentiation: Implications for Autoimmune Diseases
por: Fu, NanNan, et al.
Publicado: (2021)

Locally secreted Fc-OX40L is superior to systemic, antibody mediated, OX40 costimulation for combination immunotherapy
por: Fromm, George, et al.
Publicado: (2015)

The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response
Publicado: (1996)

Mast Cell-Derived Exosomes Promote Th2 Cell Differentiation via OX40L-OX40 Ligation
por: Li, Fei, et al.
Publicado: (2016)

Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment
por: Chen, Peixin, et al.
Publicado: (2021)

Hsa_circ_0000652 Aggravates Inflammation by Activation of Macrophages and Enhancement of OX40/OX40L Interaction in Ankylosing Spondylitis
por: Song, Minkai, et al.
Publicado: (2021)

Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma
por: Chen, Xianlong, et al.
Publicado: (2022)

A Combination of Systemic and Intracranial Anti-CD25 Immunotherapy Elicits a Long-Time Survival in Murine Model of Glioma
por: Poirier, Marie-Denise, et al.
Publicado: (2009)

Evasion of host antioxidative response via disruption of NRF2 signaling in fatal Ehrlichia-induced liver injury
por: Sharma, Aditya Kumar, et al.
Publicado: (2023)

OX40-OX40L Interaction Promotes Proliferation and Activation of Lymphocytes via NFATc1 in ApoE-Deficient Mice
por: Yan, Jinchuan, et al.
Publicado: (2013)

OX40L/OX40 Signal Promotes IL-9 Production by Mucosal MAIT Cells During Helicobacter pylori Infection
por: Ming, Siqi, et al.
Publicado: (2021)

PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
por: Guo, Zhiqiang, et al.
Publicado: (2014)

NK Cell-Mediated Regulation of Protective Memory Responses against Intracellular Ehrlichial Pathogens
por: Habib, Samar, et al.
Publicado: (2016)

New pathways in immune stimulation: targeting OX40
por: Alves Costa Silva, Carolina, et al.
Publicado: (2020)

Development of OX40 agonists for canine cancer immunotherapy
por: Ruiz, Damien, et al.
Publicado: (2022)

OX40:OX40L axis: emerging targets for improving poxvirus‐based CD8(+) T‐cell vaccines against respiratory viruses
por: Goulding, John, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_kir6ocldch6ac4jv4304ou29il